Trial Profile
A Single Arm, Prospective, Study Assessing Grazoprevir/Elbasvir plus Sofosbuvir and Ribavirin in HCV Genotype 1 or 4 Infected Patients who Failed Sofosbuvir Based Therapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- 16 Nov 2017 New trial record
- 24 Oct 2017 Results (n=17) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.